NICE rejects Mysimba (bupropion and naltrexone) as a treatment for obesity.- Orexigen
The National Institute for Health and Care Excellence (NICE) has published draft guidelines rejecting Mysimba/Contrave (bupropion and naltrexone) from Orexigen for routine NHS use.
In an Appraisal Consultation Document, NICE said it does not recommend the drug’s use for managing overweight and obesity in adults with a Body Mass Index (BMI) of 30 or more, or 27 to 30 if the patient has one or more weight-related co-morbidities. The NICE Committee said while Mysimba provides “an innovative option after lifestyle measures have failed, and where orlistat is the only pharmaceutical alternative,” there were concerns “about the validity of the economic analysis and the robustness of the results”. Therefore it was not possible to generate an accurate estimate of cost effectiveness.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins